Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing

IRVINE, California and AMSTERDAM, March 10, 2011 - Agendia, a world leader in molecular cancer diagnostics, today
announced the hiring of David Macdonald as the company's Chief Operating
Officer, Mark Willig as Executive Vice President of North American Sales, and
Doug Bradley as Vice President of Global Marketing. Macdonald has been with
Agendia for the past eight months in a consulting role and will continue to
be responsible for laboratory operations, research and development, product
support, information technology and U.S. human resources. Willig brings with
him a rich background of executive leadership experience in a variety of
commercial roles and will oversee all sales activity in North America.
Bradley will manage all strategic and tactical marketing activities.

"As Agendia grows it is vital that we continually seek out the
brightest and most innovative minds in the industry to add to our already
stellar team," said Dr. Bernhard Sixt, CEO and co-founder of Agendia. "We
have done just that with the hiring of David, Mark and Doug, who will help us
make more people aware of Agendia's truly revolutionary technology
worldwide."

Macdonald has 25 years of experience commercializing clinical
diagnostic systems and laboratory services for companies such as Nova
Biomedical, Behring Diagnostics, Nichols Institute, Quest Diagnostics,
Nanogen, Nanomix and AltheaDx. He has held CEO and COO positions for the past
18 years, and holds a Bachelor of Science degree from Northeastern University
in management and finance as well as an MBA from Babson College in marketing
and entrepreneurship.

Willig has held a number of senior leadership positions within
the healthcare industry, including General Manager and Chief Commercial
Officer at Exiqon, VP of Global Sales for Thermo Fisher's $300 million
anatomic pathology business unit, Executive Vice President of Sales and
Marketing at Specialty Labs, Vice President of Sales at Myriad Genetics, as
well as 12 years in commercial roles of increasing responsibility at Abbott
Diagnostics. He holds a Bachelor of Science degree from the University of
Missouri.

Bradley brings a wealth of leadership experience in medical
and pharmaceutical product marketing at companies including Coherent Medical,
Allergan and SenoRx. Most recently, he served as Vice President of Marketing
at Vertos Medical. In his eight years at Irvine-based SenoRx, Bradley led the
company's marketing activities from its infancy. In this role, Bradley became
intimately familiar with medical devices for the diagnosis and treatment of
breast cancer. During Bradley's time at SenoRx, they received the "Technology
Fast 50" award from Deloitte & Touch in 2006, 2007 and 2008. He holds a
Bachelor of Science degree in Microbiology from the University of Oklahoma
and an MBA from Pepperdine University.

About Agendia

Agendia (www.Agendia.com) is at the forefront of the
personalized medicine revolution, striving to bring more effective,
individualized treatments within reach of patients. Building on a
cutting-edge genomics platform for tumor gene expression profiling, the
company's tests help physicians more accurately tailor cancer treatments.
Agendia markets four products, with several new genomic tests under
development. In addition, Agendia collaborates with pharmaceutical companies
to develop highly effective personalized drugs in the area of oncology.
Agendia is based in Irvine, California, and in Amsterdam, the Netherlands.

MEDIA CONTACT: Valerie Carter, Ricochet Public Relations, +1-202-316-0143 Mobile, vcarter at ricochetpr.com